Canada: Sanofi-Aventis, et al. v. Apotex Inc., et al.

Last Updated: November 25 2014
Article by Adam Bobker and Nathan Haldane

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis, et al, 2014 FCA 68.

Sanofi owned a series of patents for the drug Ramipril, the last of which were set to expire in 2005. In anticipation of the expiry, Apotex had received certain regulatory approvals from Health Canada in 2004; however, it did not receive its Notice of Compliance (NOC) until December 12, 2006. This was due to the fact that Sanofi exercised its rights under the PM (NOC) Regulations for a statutory stay of the issuance, which was later found unsustainable. Sanofi acknowledged that Apotex was entitled to damages for the delay but at issue were the relevant dates for computing the loss and the various assumptions and projections built into the assessment of damages.

In order to determine damages, the Trial Judge applied the test from Apotex Inc. v. Merck & Co. , 2011 FCA 329 that requires the Judge to consider the hypothetical question: What would have happened if Sanofi had not brought an application for prohibition? The parties disagreed on the outcome of eight factors that would determine the scope of Apotex's losses. 

In regards to the relevant date for computing the loss suffered by Apotex, the Court looked at all of the Prohibition Orders obtained by Sanofi. Apotex had originally served a notice of allegation in August, 2003, alleging non-infringement of Sanofi's patent. Sanofi then attempted to obtain a Prohibition Order and was successful, effectively blocking the Minister from issuing a NOC. In November of 2003, Apotex filed a second notice of allegation, this time alleging invalidity of the patent. Once again, Sanofi attempted to obtain a Prohibition Order, however this time they were refused by the Court and Sanofi launched an appeal. Before the appeal could be heard, the patent expired and the appeal was dismissed for mootness. The Federal Court found that the second allegation effectively "unlocked" the door for Apotex to receive a NOC and therefore relevant date for assessing damages was the date that the Minister would have issued a NOC, April 26, 2004. 

In assessing the relevant end date for assessing damages, Apotex argued that the correct date was May 2, 2008; the dismissal date of the last Prohibition proceeding. However, the Prothonotary dismissed the Prohibition application as moot, as the NOC had already been issued on December 12, 2006. Sanofi argued that the correct end date was June 27, 2006, the date Apotex ceased to be a "second person" for the purposes of the NOC Regulations. The Court rejected this argument as well, stating that the purpose of S. 8 of the NOC Regulations was to compensate "a second person for the loss occasioned by the operation of the statutory stay." When Apotex received its NOC on December 12, 2006, they could no longer claim to be at a loss and so the Court decided that December 12, 2006 was the relevant end date for assessing damages. The FCA agreed with the Federal Court on both the start and end dates for assessing the liability period. 

The Trial Judge then turned to an assessment of Apotex's lost profits based on what their share of the market would have looked like in a "but, for" world. The Court considered the testimony from experts on both sides and determined what the market for generic Ramipril would have been during the liability period. The Court then turned its attention to assessing what share of the generic market Apotex would have received during the liability period. In considering this, one of the most contentious factors was at what theoretical point other generic manufacturers would have entered the market. Teva had made plans to enter the generic market but was prepared to wait until the expiration of the '457 Patent in December of 2005. Considering the regulatory impediments it would have then encountered, the Trial Judge decided that their date of market entry would have been August 1, 2006. Riva had also made plans to enter the generic market but due to the fact it had cross-referenced its own application to that of Pharmascience and the resulting regulatory hurdles, Riva could not have entered the market until June 21, 2007, after the liability period had expired. Lastly, the trial judge also considered whether an "authorized generic", meaning a drug manufactured by an innovative drug company but sold by a generic company under a generic's name, would have also entered the generic market. The Trial Judge found that it was more likely than not that it would have entered the market, however Apotex's launch would have surprised the innovator and therefore, it would take three months for an authorized generic to enter the market. The Trial Judge selected July 26, 2004 as the likely entry period for the authorized generic. The FCA found that the Trial Judge erred in finding that Teva would have entered the generic market during the liability period, as they found that they would have acted the same in the hypothetical world as they did in the real world. Since they actually did not receive summary dismissal from their Prohibition Applications until December 16, 2006, the FCA found that this is the date they would have entered the generic market, outside the liability period. Therefore, the only competing generic on the market at the time would have been the authorized generic.

The Trial Judge then took the hypothetical entry dates and determined what Apotex's share of the market would have been during the liability period based on who else was in the market. The original Apotex decision had been handed down at the same time as an identical case dealing with what liability Sanofi owed Teva. The Trial Judge divided the generic market based on the hypothetical dates of entry. In the immediate period after Teva entered the generic market, Apotex was to be granted damages representing 70 percent of the market, Teva was to receive 30 percent of the market and the authorized generic would receive 33 percent of the market. Though the Trial Judge accepted that the arithmetic exceeded the total revenue for the market, she rejected Sanofi's argument that there should be only a "single hypothetical market" for the generic product since the "assessment of damages can and should be made on the facts of each case" and that the evidence provided in separate trials led to different conclusions. The majority in the FCA decision agreed and pointed to the fact that the Regulations only expressed that they should be disregarded in constructing one element of the hypothetical generic market. Since it was stated for only one purpose, to read in another would amount to judicially amending S. 8 of the Regulations. 

This methodology was rejected by the minority in the FCA who found that the evidence in both cases was largely the same. The minority found that the proper approach is to construct a hypothetical market that most resembles a real market. In constructing a "real market" the minority found that once a Prohibition Order is refused, the innovating drug company cannot litigate the same issues repeatedly with other generic drug manufacturers. Therefore, it will only be minor regulatory restraints that prevent all the generics from entering the hypothetical real market. This approach creates a "hypothetical market reflecting a level regulatory playing field" and the minority would have sent the matter back to the Federal Court to be re-assessed using these guidelines. 

Also at issue between the parties was whether the "ramp-up" period should be counted twice. A ramp-up period is the time it takes a drug manufacturer to penetrate the market to its full potential. Apotex argued that it already experienced a ramp-up period after they received their NOC, so including a ramp-up period in the damages calculations essentially imposes the penalty twice. The Trial Judge rejected the ramp-up claim because the loss occurred outside of the S. 8 liability period, namely the period of time they were prevented from entering the market. The majority agreed, however the minority would have reversed the Trial Judge's decision to include the second ramp-up period and found that in these cases it is appropriate to exercise discretion and consider the actual ramp-up period as a relevant factor.  

The last issue decided by the Trial Judge and heard on appeal dealt with the so-called HOPE Patents and whether Apotex's compensation could extend to sales of its generic drug for unapproved indications. The drug Ramipril had originally been approved for hypertension; however, further testing revealed it was also beneficial for heart-related health issues and Sanofi had filed two further patents for Ramipril, known as the HOPE Patents, for further uses. The Trial Judge found that some sales of the generic product would have related to the HOPE indications since (a) generic products are not promoted for specific uses, (b) off-label subscribing and substitution commonly take place, (c) Sanofi had not opposed the generic version as being fully interchangeable, and (d) Sanofi could begin an action for patent infringement if they thought it was reasonable to do so. The FCA agreed with the Trial judge and Sanofi's arguments were rejected. 

It is unclear whether the decision on start and end dates will once again be brought before the Supreme Court, however it is clear that the Supreme Court will have to decide the proper way for deciding which generics will enter the market and when they would have done so in a hypothetical world. It will also hopefully clarify what a Court is expected to do when facing more than one trial on for the same patent; create one hypothetical world combining the evidence from both or treat each separately and confine the hypothetical world to the one before the Court.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
Nathan Haldane
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.